x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

34:07

319: BioMarin's executive shakeup, a GLP-1 lowers...

The Readout Loud ·

2024/08/22

It's a guest-free episode this week, giving Allison, Adam and Elaine ample time to chat about the management shakeup at BioMarin, including the announcement that James Sabry, the former Roche dealmaker, was joining the company as its new chief business officer. We can't seem to go a week without talking about GLP-1 medicines, so in true form, Elaine walks us through new study findings that showed Lilly's Zepbound greatly reduced the risk of diabetes. We also discuss a separate study that potentially

en

21:16

318: Drug pricing drops & psychedelics under fire

The Readout Loud ·

2024/08/15

STAT’s chief Washington correspondent Rachel Cohrs Zhang joins us to discuss the discounts and how this first round of negotiations between pharmaceutical companies and Medicare officials played out. After that, we chat with our colleague Meghana Keshavan about the latest news in the psychedelics world, including the retraction of three research papers.

en

28:52

317: VC struggles, drug pricing negotiations, &...

The Readout Loud ·

2024/08/08

STAT's Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI drug development companies Recursion Pharmaceuticals and Exscientia, Novo Nordisk's decision to pause its regulatory submission for Wegovy's use in patients with heart failure with preserved ejection fraction, and the state of biotech VC.

en

34:15

316: The long journey to make malaria vaccines, and...

The Readout Loud ·

2024/08/01

Andrew Joseph, STAT's Europe correspondent, joins us to talk about his special report on the 40-year quest to develop the world's first malaria vaccines. We also cover the latest news in the biotech industry, including Sarepta Therapeutics' move to censor a patient video, data from a new Duchenne gene therapy, and a campaign by Mount Sinai to stifle debate about its controversial brain research following revelations made by a STAT investigation.

en

32:46

315: UnitedHealth's doctor empire, an FDA departure,...

The Readout Loud ·

2024/07/25

What makes UnitedHealth similar to Standard Oil? Is Viking Therapeutics an attractive acquisition target? And is Adam good at math?We discuss all that and more in this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tara Bannow, our hospitals and insurance reporter, joins us to talk about a new investigation that shows how UnitedHealth wields its unrivaled physician empire to boost its profits and expand its influence. We also cover the latest news in the life sciences, including

en

33:02

314: JD Vance's biotech ties, Cassava resignations,...

The Readout Loud ·

2024/07/18

Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.

en

34:52

313: Biotech layoffs, founder-focused VC, & a big...

The Readout Loud ·

2024/07/11

STAT's West Coast biotech reporter Jonathan Wosen joins "The Readout LOUD" to discuss what’s driving workforce cuts. Plus, entrepreneurs Alexis Borisy and Zach Weinberg call in to discuss their biotech incubator Curie.Bio and how they hope to “free the founders.” We also discuss a big change in Pfizer’s leadership and the debate over a new side effect tied to the diabetes drug Ozempic.

en

28:33

312: Medicare coverage for GLP-1 drugs, AI, and...

The Readout Loud ·

2024/06/27

STAT health tech reporter Brittany Trang guest co-hosts "The Readout LOUD" this week, where we discuss AI for drug development, the latest in the H5N1 bird flu outbreak, a surprise entrant to the GLP-1 field, and more news in the life sciences. And STAT chief Washington correspondent Rachel Cohrs Zhang joins the podcast to talk about a new proposal for obesity drug coverage in Washington and what to expect from the first presidential debate.

en

34:10

311: Fauci's memoir, Alnylam's tenuous trial, and a...

The Readout Loud ·

2024/06/20

STAT reporter Jason Mast joins us to discuss Anthony Fauci's memoir "On Call," which was published this week. Hosts Allison DeAngelis and Adam Feuerstein also dissect Alnylam's forthcoming clinical trial data and take stock of how the biotech markets are succeeding and potentially falling flat midway through the year.For more on Fauci's memoir "On Call," go here; for Adam's primer on Alnylam's ATTR-CM trial, go here; read about BridgeBio's plans here; and for more on biotech startup financing, go

en

38:46

310: Duchenne gene therapy setback, Alzheimer's drug...

The Readout Loud ·

2024/06/13

STAT's Nicholas Florko joins to explain what it means to be a reporter writing about the commercial determinants of health. Hint: Florko's most recent stories focus on weed, vapes, and raw milk. And instead of being chained to a desk, he often drives around to convenience stores and buy bad stuff — all in the name of good journalism. But first, co-hosts Adam Feuerstein and Allison DeAngelis chat about Pfizer's Duchenne gene therapy setback, the likely approval of a new treatment for Alzheimer's

en

29:34

309: Psychedelics at the FDA, ASCO recap, & MorphoSys...

The Readout Loud ·

2024/06/06

STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics' meeting with an FDA advisory committee. We also discuss the latest news in the health and life sciences, including stories from major biotech conferences.To learn more about Lykos' advisory committee meeting, go here; for more on the tumult at BIO, go here; for a recap of ASCO, go here; to read the latest on Novartis' acquisition of MorphoSys, go here. And you can sign up for Adam’s new newsletter, Biotech Scorecard, here.

en

28:41

308: An ASCO preview & another Duchenne trial failure

The Readout Loud ·

2024/05/30

We preview some of the research that will be presented at The American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure. To read more about Merus' combination therapy, go here; For more on Johnson & Johnson's mixed data, click here; For more on Nippon Shinyaku's Duchenne drug trial failure, go here; To read more on Insmed's

en

31:12

307: More tumult at BIO & coercive care for sickle...

The Readout Loud ·

2024/05/23

This week on “The Readout LOUD,” STAT's Chief Washington Correspondent Rachel Cohrs Zhang joins us to discuss the layoffs at trade group BIO and how things may be changing at the trade group. We also invite STAT reporter Eric Boodman on to talk about his new investigative series of stories exploring how Black women with sickle cell disease were coerced into getting sterilized.

en

23:08

306: Live! From the STAT Breakthrough Summit West

The Readout Loud ·

2024/05/16

On this week’s "Readout LOUD," we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI correspondent — and recent Pulitzer finalist — Casey Ross, who sat down on stage to discuss AI-centered drug discovery with both NVIDIA and Google-backed Isomorphic Labs. We also discuss this week’s biotech news, including yet more obesity drug data, this time from Roche, and the closing of Novartis’ acquisition of MorphoSys.

en

31:52

305: Everything you need to know about H5N1 bird flu

The Readout Loud ·

2024/05/09

This week on "The Readout LOUD," STAT senior infectious diseases reporter Helen Branswell walks us through ongoing H5N1 outbreak in the U.S. and issues with monitoring the spread. And in a bit of shameless self-promotion, we’ll talk to our colleagues Bob Herman and Casey Ross about being named Pulitzer finalists in investigative reporting for their reporting on United Healthcare’s use of algorithms in coverage decisions. We'll hear what’s happened since their explosive work was published last

en

33:04

304: Controversial brain tissue research, obesity...

The Readout Loud ·

2024/05/02

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation. We also discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli

en

31:45

303: A new obesity startup, an acquisition gone...

The Readout Loud ·

2024/04/18

We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field.Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care

en

24:48

302: Vertex's big deal, biotech's red numbers, & an...

The Readout Loud ·

2024/04/11

How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon?We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. We also explain why gas prices are weighing on biotech, and make a surprise announcement.

en

31:37

301: Biotech mega-rounds, a cancer vaccine setback &...

The Readout Loud ·

2024/04/04

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans. Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner

en

34:21

300: What the mifepristone case means, GLP-1...

The Readout Loud ·

2024/03/28

Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the development of new medicines. We also discuss the latest news in the life sciences, including a contrarian take on a new obesity treatment, a congressional effort to ban Chinese biotech companies, and how we managed to make 300 episodes of this podcast.Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can

en

381 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...